Inclusive of all taxes
TELMISIGN TRIO Tablet by Dr Precision is an advanced fixed-dose triple-combination antihypertensive medication formulated specifically for patients requiring intensive blood pressure control. It combines Telmisartan (an angiotensin II receptor blocker), Amlodipine (a calcium channel blocker), and Hydrochlorothiazide (a thiazide diuretic) in a single tablet to provide comprehensive management of hypertension, particularly in patients with comorbid cardiovascular risks such as left ventricular hypertrophy, diabetes, or renal impairment. This synergistic triple-action approach targets multiple pathways involved in blood pressure regulation—vasodilation, reduction of vascular resistance, and decreased blood volume—ensuring sustained 24-hour blood pressure control. Manufactured under stringent GMP, WHO-GMP, and ISO-certified conditions with full compliance to international pharmacopoeial standards, TELMISIGN TRIO ensures consistent quality, safety, and efficacy. Its once-daily dosing enhances patient adherence by minimizing pill burden, and tamper-proof, moisture-resistant packaging prolongs shelf life even in humid climates. Clinically validated mechanisms of action and extensive quality control measures make TELMISIGN TRIO a superior choice for healthcare providers managing patients with complex hypertension profiles, facilitating reduction of cardiovascular events such as stroke and heart attack. This product requires appropriate clinical monitoring and is contraindicated in pregnancy, severe renal or hepatic dysfunction, and sulfonamide hypersensitivity.
Key Features
| Features | Description |
|---|---|
| Active Ingredients | Telmisartan, Amlodipine, Hydrochlorothiazide |
| Therapeutic Use | Triple-combination antihypertensive for multi-drug therapy in hypertension management |
| Mechanism of Action | Telmisartan inhibits angiotensin II receptors; Amlodipine blocks calcium channels; Hydrochlorothiazide acts as diuretic |
| Indications | For patients inadequately controlled on dual therapy with coexisting cardiovascular risks |
| Dosing Schedule | Once daily |
| Manufacturing Standards | Produced in GMP, WHO-GMP, and ISO-certified facilities |
| Quality Control | Involves assays for active ingredients, blend uniformity, dissolution, impurities, and microbial testing |
| Packaging | Tamper-proof, moisture-resistant packaging for extended shelf life |
| Contraindications | Pregnancy, severe renal/hepatic dysfunction, sulfonamide hypersensitivity |
| Clinical Benefits | Reduces risk of stroke, heart attack, kidney complications with sustained 24-hour blood pressure control |
| Attributes | Description |
|---|---|
| Formulation Type | Fixed-dose combination tablet |
| Dosage Strength | Variable strengths combining Telmisartan, Amlodipine, and Hydrochlorothiazide |
| Pharmacological Class | Angiotensin II receptor blocker, Calcium channel blocker, Thiazide diuretic |
| Shelf Life | Typically 24 months in recommended storage conditions |
| Storage Conditions | Store in a cool, dry place away from direct sunlight and moisture |
| Packaging Type | Blister packs in tamper-evident, moisture-resistant material |
| Safety Monitoring | Requires periodic kidney function, electrolyte levels, and blood pressure checks during therapy |
| Regulatory Compliance | Complies with international pharmacopoeial and pharmaceutical manufacturing standards |
| Manufacturer | Dr Precision under BluepillExpress global pharmaceutical compliance framework |
| Common Side Effects | Dizziness, fatigue, ankle swelling, mild electrolyte imbalance (infrequent) |
*Disclaimer: The above description has been AI-generated and has not been audited or verified for accuracy. It is recommended to verify product details independently before making any purchasing decisions.
TELMISIGN TRIO integrates three antihypertensive agents acting via different mechanisms—angiotensin II receptor blockade, calcium channel blockade, and diuretic effect—providing a broader and more effective 24-hour blood pressure control for patients who do not respond adequately to dual therapy.
Beyond blood pressure reduction, TELMISIGN TRIO helps reduce left ventricular hypertrophy and protect renal function due to its combination of Telmisartan and Hydrochlorothiazide. These actions contribute to lowering risks of stroke, heart attack, and kidney complications, especially in patients with comorbid conditions.
TELMISIGN TRIO manufacturing includes GMP, WHO-GMP, and ISO certifications with rigorous analytical validation such as active ingredient assay, blend uniformity testing, dissolution profiling, impurity checks, and microbial testing to ensure consistent quality and safety.
Yes, TELMISIGN TRIO should not be used in pregnant women, patients with severe renal or hepatic impairment, and individuals with known hypersensitivity to sulfonamide-derived drugs. Caution is also advised in patients experiencing electrolyte imbalances or volume depletion.
The tamper-proof and moisture-resistant packaging preserves the tablet's integrity and efficacy throughout its shelf life, especially important in regions with high humidity or variable storage conditions.
Periodic monitoring of kidney function, electrolyte levels, and blood pressure is essential to detect any adverse effects or imbalances, ensuring safe and effective long-term therapy, particularly in elderly or renal-compromised patients.
Country Of Origin: India
TELMISIGN TRIO Tablet is a triple-combination antihypertensive formulation containing Telmisartan, Amlodipine, and Hydrochlorothiazide. It is designed for effective and comprehensive management of high blood pressure in patients requiring multidrug therapy, helping reduce cardiovascular risks and promoting long-term blood pressure control.
This product is manufactured under the Dr Precision label, ensuring GMP-compliant quality and precision formulation standards.
TELMISIGN TRIO Tablet is a fixed-dose combination of three proven antihypertensive agents: Telmisartan (an angiotensin II receptor blocker), Amlodipine (a calcium channel blocker), and Hydrochlorothiazide (a thiazide diuretic). This triple-action formulation is crafted for patients who do not achieve adequate blood pressure control with dual therapy alone, and who require a more intensive and consolidated approach to managing hypertension.
Telmisartan works by inhibiting the angiotensin II receptor, leading to vasodilation and a reduction in systemic vascular resistance. Amlodipine, by blocking calcium channels in the vascular smooth muscle, complements Telmisartan’s action by further relaxing the blood vessels and reducing the workload on the heart. Hydrochlorothiazide, meanwhile, increases the excretion of sodium and water from the kidneys, reducing blood volume and thereby further lowering blood pressure. Together, these agents work synergistically to deliver consistent, 24-hour blood pressure control.
TELMISIGN TRIO is particularly effective for hypertensive patients with coexisting cardiovascular risks such as left ventricular hypertrophy, renal impairment, diabetes, or obesity. The once-daily dosing simplifies treatment protocols, improves patient adherence, and minimizes pill burden.
Manufactured under the global pharmaceutical compliance framework of BluepillExpress, TELMISIGN TRIO is developed in GMP, WHO-GMP, and ISO-certified facilities. The product undergoes extensive analytical validation, including assays for individual active ingredients, blend uniformity, dissolution profiles, impurity profiling, and microbial testing. Each batch is rigorously checked for compliance with international pharmacopoeial standards before release.
Clinically, TELMISIGN TRIO helps reduce the risk of stroke, heart attack, and kidney complications related to uncontrolled hypertension. Patients report good tolerability, with adverse effects such as dizziness, fatigue, ankle swelling, or mild electrolyte imbalance occurring infrequently. Periodic monitoring of kidney function, electrolytes, and blood pressure is advised during chronic use, particularly in elderly or renal-compromised individuals.
The product is available in tamper-proof, moisture-resistant packaging, ensuring a long shelf life and product integrity even in high-humidity regions. TELMISIGN TRIO offers a comprehensive and clinically validated solution for high-risk hypertensive patients in need of robust, multi-faceted blood pressure management.
It is contraindicated in pregnancy, patients with severe renal or hepatic dysfunction, and in those with hypersensitivity to sulfonamide-derived drugs. Care should also be taken in patients with electrolyte imbalance, volume depletion, or severe cardiac failure.
With TELMISIGN TRIO, BluepillExpress delivers a globally competitive, high-efficacy solution for physicians aiming to optimize hypertension outcomes in complex cases.
Inclusive of all taxes
You Save: 0
Surat , India
Manufacturer, Contractor, Retailer, Brand Owner, Distributor, Exporter, Importer, Wholesaler, Startup
GST- 24abdfb4194j1ze
